Skip to main content
. 2021 May 7;8(14):2004873. doi: 10.1002/advs.202004873

Figure 4.

Figure 4

Drug delivery regularity of TAILI, Conv‐DMN, and Candlelit‐DMN using ex vivo human skin on the surface. a) Schematics of viewpoint for images in (b) and (c). b) Stereoscopic images of remnant DMN structures after applying Conv‐DMN and Candlelit‐DMN. (orange arrowhead: remnant DMN structure) c) Stereoscopic images of ex vivo human skin after TAILI or application of Conv‐DMN and Candlelit‐DMN (dotted yellow line: TA application site of each group) for 30 min at 10‐min intervals. Black bar: 500 µm; White bar: 5 mm.